biomarker-directed biscay data: durvalumab plus targeted therapies in muc
Published 4 years ago • 165 plays • Length 3:00Download video MP4
Download video MP3
Similar videos
-
1:25
biomarker-directed, multi-drug, phase 1b trial in bladder cancer
-
1:29
biscay trial for bladder cancer - trial design and its potential impact on clinical practice
-
0:49
the need for biomarkers to aid in treatment decision making for upper tract urothelial carcinoma
-
2:16
savolitinib plus durvalumab show promise in papillary renal cancer: calypso results
-
1:00
trial of durvalumab for bladder cancer
-
1:31
novel therapies for the treatment of bladder cancer
-
2:18
btcrc-gu15-023: duart plus adjuvant durvalumab in bladder cancer
-
5:08
update on biomarkers in urothelial cancer presented at esmo 2020
-
1:54
dr. wistuba on biomarkers for immunotherapy in lung cancer
-
4:20
imvigor130 data: atezolizumab alone or with chemo upfront for bladder cancer
-
2:04
unmet need in bladder cancer
-
2:00
durvalumab plus danvatirsen for r/m hnscc: exciting scores data
-
0:38
targetable alterations in bladder cancer
-
3:41
what is a biomarker? - bladder cancer video library
-
3:03
what is a biomarker? - bladder cancer video library
-
2:30
abacus updates: positive results for preoperative atezolizumab in bladder cancer
-
4:11
what's next for checkpoint inhibitors in metastatic urothelial bladder cancer?
-
4:25
kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer